Common Stock, Special Common Stock and Redeemable Common Stock Information

Stock Trading Symbol: DNA

Stock Exchange Listings
Our Common Stock began trading on the New York Stock Exchange under the symbol “DNA” on July 20, 1999. On June 30, 1999, we redeemed all of our outstanding Callable Putable Common Stock, or Special Common Stock, held by stockholders other than Roche Holdings, Inc. (or Roche). Our Special Common Stock had traded on the New York Stock Exchange and the Pacific Exchange under the symbol “GNE” from October 26, 1995, through June 16, 1999. On October 25, 1995, our non-Roche stockholders approved an agreement with Roche, referred to herein as the “Agreement.” Pursuant to the Agreement, each share of our Common Stock not held by Roche or its affiliates automatically converted to one share of Special Common Stock. From July 3, 1995, through October 25, 1995, our Common Stock was traded on the New York Stock Exchange under the symbol “GNE.” After the close of business on June 30, 1995, each share of our Redeemable Common Stock automatically converted to one share of Common Stock. The conversion was in accordance with the terms of the Redeemable Common Stock put in place at the time of its issuance on September 7, 1990, when our merger with a wholly owned subsidiary of Roche was consummated. Our Redeemable Common Stock traded on the New York Stock Exchange under the symbol “GNE” from September 10, 1990, to June 30, 1995. Our Common Stock was traded on the New York Stock Exchange under the symbol “GNE” from March 2, 1988, until September 7, 1990, and on the Pacific Exchange under the symbol “GNE” from April 12, 1988, until September 7, 1990. Our Common Stock was previously traded in the NASDAQ National Market System under the symbol “GENE.” No dividends have been paid on the Common Stock, Special Common Stock or Redeemable Common Stock. We currently intend to retain all future income for use in the operation of our business and, therefore, do not anticipate paying any cash dividends in the foreseeable future.

Common Stockholders
As of December 31, 2001, there were approximately 1,621 stockholders of record of our Common Stock, one of which is Cede & Co., a nominee for Depository Trust Company or DTC. All of the shares of Common Stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC, and are therefore considered to be held of record by Cede & Co. as one stockholder.

Stock Prices

Headquarters
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
(650) 225-1000
www.gene.com

Stock Listing

		Genentech is listed on the New York Stock exchange under the symbol DNA.

Transfer Agent
Communications concerning transfer requirements, lost certificates and change of address should be directed to Genentech’s transfer agent:

EquiServe, LP
Stockholder Services
Post Office Box 43010
Providence, Rhode Island 02940-3010

Telephone: (800) 733-5001
Fax: (781) 828-8813
www.equiserve.com

Annual Meeting
The annual meeting of stockholders will be held at 10:00 a.m. Pacific time on April 11, 2002, at The Westin Hotel, 1 Old Bayshore Highway, Millbrae, California. Detailed information about the meeting is contained in the Notice of Annual Meeting and Proxy Statement sent to each stockholder of record as of February 11, 2002.

Investor Relations
Genentech invites stockholders, security analysts, representatives of portfolio management firms and other interested parties to contact:

Michael Burchmore, Pharm.D.
Director, Investor Relations
(650) 225-8852 phone
(650) 225-8326 fax

Katherine Littrell, Ph.D., R.N.
Associate Director, Investor Relations
(650) 225-1034 phone
(650) 225-8326 fax

Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
e-mail: investor.relations@gene.com

Additional Information
If you need additional assistance or information regarding the company, or would like to receive a free copy of Genentech’s Form 10-K and 10-Q reports filed with the Securities and Exchange Commission, contact the Investor Relations Department at Genentech’s corporate offices by sending an e-mail message to investor.relations@gene.com or calling (650) 225-1599. You can direct requests for literature to Genentech’s literature request line at (800) 488-6519, or you can visit Genentech’s site on the World Wide Web at www.gene.com.

Independent Auditors
Ernst & Young LLP
Palo Alto, California

Want to learn more about Genentech?
Visit us on the World Wide Web: www.gene.com